Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 11/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12229831 | 0.93 | MAP2 (0.46) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL12229837 | 0.92 | MAP2 (0.52) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL12230137 | 0.91 | ALDH1A1 (0.46) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL12229848 | 0.91 | MAP2 (0.45) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL14114291 | 0.91 | MAP2 (0.45) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL12229853 | 0.90 | MAP2 (0.45) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL12229830 | 0.90 | CNR1 (0.46) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL12229832 | 0.89 | CNR1 (0.44) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL12229829 | 0.88 | MAP2 (0.45) | MAP2ALDH1A1HPGDCYP1A2XBP1 | |
| SCHEMBL14036299 | 0.88 | MAP2 (0.45) | MAP2ALDH1A1HPGDCYP1A2XBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044091-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044091-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044091-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2256124-A1 | Phospho-indoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-2256124-A1 | Phospho-indoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2010-12-01 | — | — | EP | disclosed |
| EP-1961757-B1 | Phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1961757-B1 | Phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-7534809-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534809-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534809-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1799696-B1 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1799696-B1 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1961757-A1 | Phosphoindoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1961757-A1 | Phosphoindoles as HIV inhibitors | IDENIX Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2006054182-A9 | PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX CAYMAN LTD | 2006-08-17 | — | — | WO | disclosed |
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS LLC | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074054-A1 | Phospho-indoles as HIV inhibitors | IDO1, PPP5C, INMT | MAP2 320/4885ALDH1A1 4061/4885HPGD 3388/4885 |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDO1, PPP5C, INMT | MAP2 320/4885ALDH1A1 4061/4885HPGD 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.